S&P 500   4,244.76 (-1.02%)
DOW   33,150.05 (-0.85%)
QQQ   356.92 (-1.20%)
AAPL   171.28 (-1.42%)
MSFT   316.65 (-1.60%)
META   302.36 (-1.45%)
GOOGL   132.86 (-0.98%)
AMZN   125.88 (-2.77%)
TSLA   247.59 (-1.59%)
NVDA   445.65 (-0.48%)
NIO   8.64 (-1.71%)
BABA   84.39 (-2.47%)
AMD   102.29 (-0.95%)
T   14.74 (+0.48%)
F   12.11 (-1.62%)
MU   68.62 (+0.97%)
CGC   0.70 (-4.91%)
GE   108.45 (-0.31%)
DIS   80.76 (-1.11%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.79 (-1.31%)
NFLX   383.91 (+0.94%)
S&P 500   4,244.76 (-1.02%)
DOW   33,150.05 (-0.85%)
QQQ   356.92 (-1.20%)
AAPL   171.28 (-1.42%)
MSFT   316.65 (-1.60%)
META   302.36 (-1.45%)
GOOGL   132.86 (-0.98%)
AMZN   125.88 (-2.77%)
TSLA   247.59 (-1.59%)
NVDA   445.65 (-0.48%)
NIO   8.64 (-1.71%)
BABA   84.39 (-2.47%)
AMD   102.29 (-0.95%)
T   14.74 (+0.48%)
F   12.11 (-1.62%)
MU   68.62 (+0.97%)
CGC   0.70 (-4.91%)
GE   108.45 (-0.31%)
DIS   80.76 (-1.11%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.79 (-1.31%)
NFLX   383.91 (+0.94%)
S&P 500   4,244.76 (-1.02%)
DOW   33,150.05 (-0.85%)
QQQ   356.92 (-1.20%)
AAPL   171.28 (-1.42%)
MSFT   316.65 (-1.60%)
META   302.36 (-1.45%)
GOOGL   132.86 (-0.98%)
AMZN   125.88 (-2.77%)
TSLA   247.59 (-1.59%)
NVDA   445.65 (-0.48%)
NIO   8.64 (-1.71%)
BABA   84.39 (-2.47%)
AMD   102.29 (-0.95%)
T   14.74 (+0.48%)
F   12.11 (-1.62%)
MU   68.62 (+0.97%)
CGC   0.70 (-4.91%)
GE   108.45 (-0.31%)
DIS   80.76 (-1.11%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.79 (-1.31%)
NFLX   383.91 (+0.94%)
S&P 500   4,244.76 (-1.02%)
DOW   33,150.05 (-0.85%)
QQQ   356.92 (-1.20%)
AAPL   171.28 (-1.42%)
MSFT   316.65 (-1.60%)
META   302.36 (-1.45%)
GOOGL   132.86 (-0.98%)
AMZN   125.88 (-2.77%)
TSLA   247.59 (-1.59%)
NVDA   445.65 (-0.48%)
NIO   8.64 (-1.71%)
BABA   84.39 (-2.47%)
AMD   102.29 (-0.95%)
T   14.74 (+0.48%)
F   12.11 (-1.62%)
MU   68.62 (+0.97%)
CGC   0.70 (-4.91%)
GE   108.45 (-0.31%)
DIS   80.76 (-1.11%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.79 (-1.31%)
NFLX   383.91 (+0.94%)
NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News

$5.84
-0.05 (-0.85%)
(As of 10:21 AM ET)
Compare
Today's Range
$5.64
$5.91
50-Day Range
$5.89
$9.28
52-Week Range
$2.36
$9.79
Volume
229,555 shs
Average Volume
308,459 shs
Market Capitalization
$318.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
154.7% Upside
$15.00 Price Target
Short Interest
Bearish
19.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
1.13mentions of ORIC Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$118,900 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.96) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

454th out of 975 stocks

Pharmaceutical Preparations Industry

201st out of 455 stocks


ORIC stock logo

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Price History

ORIC Stock News Headlines

ORIC Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at Wedbush
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Oric Pharmaceuticals (ORIC) Receives a Buy from Robert W. Baird
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Why Oric Pharmaceuticals Stock Is Shooting Higher Today
Why Shares of Oric Pharmaceuticals Jumped Monday
ORIC Pharma Surges On $85 Mln Private Placement Financing
See More Headlines
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+154.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-89,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.62 per share

Miscellaneous

Free Float
51,621,000
Market Cap
$321.18 million
Optionable
Not Optionable
Beta
0.92
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 66)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $93k
  • Dr. Jacob M. Chacko M.B.A. (Age 44)
    M.D., Pres, CEO & Director
    Comp: $921.32k
  • Mr. Dominic G. Piscitelli CPA (Age 48)
    CPA, M.B.A., Chief Financial Officer
    Comp: $636.91k
  • Dr. Pratik S. Multani M.D. (Age 56)
    M.S., Chief Medical Officer
    Comp: $686.88k
  • Dr. Charles L. Sawyers B.A. (Age 64)
    BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 59)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 50)
    J.D., M.D., Gen. Counsel
  • Mr. Daniel Iazzetti
    VP & Head of People
  • Dr. Edna Chow Maneval (Age 63)
    Sr. VP of Clinical Devel.













ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price forecast for 2023?

7 brokerages have issued 12 month price targets for ORIC Pharmaceuticals' shares. Their ORIC share price forecasts range from $8.00 to $27.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 154.7% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2023?

ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has increased by 0.0% and is now trading at $5.89.
View the best growth stocks for 2023 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Thursday, August, 10th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.08.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

What is ORIC Pharmaceuticals' stock symbol?

ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ORIC Pharmaceuticals' stock price today?

One share of ORIC stock can currently be purchased for approximately $5.89.

How much money does ORIC Pharmaceuticals make?

ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $321.18 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact ORIC Pharmaceuticals?

ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -